An observational study in Coronary Artery Disease, Cardiovascular Diseases and Atherosclerosis Cardiovascular Disease, sponsored by Vorarlberg Institute for Vascular Investigation and Treatment. Recruiting at 1 site in Austria. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Vorarlberg Institute for Vascular Investigation and Treatment · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 94 studies in Coronary Artery Disease with a site in Austria — 18 open to participants now, 25 under way, 3 of them phase 3. Coronary Artery Disease · Austria.
Among the 94 studies in Coronary Artery Disease with a site in Austria, this one is the 10th largest by planned enrollment of the 27 observational ones that give a count, is one of 3 that started in 2022, is one of 27 observational ones, reaches primary completion later than 23 of the 24 other live ones, and was the 94th registered.
4,861 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.
Browse Coronary Artery Disease studies →18 of the 94 studies in Coronary Artery Disease with a site in Austria are open now. Recruiting first, the newest first:
Medical University Innsbruck · Sites in Austria
Ages 18+
Teleflex · Sites in Austria, United States, France and 3 more countries
Ages 18+
Ludwig Boltzmann Gesellschaft · Sites in Austria
Ages 18–65
CSL Behring · Sites in Austria, United States, Argentina and 32 more countries
Ages 18+
Medical University Innsbruck · Sites in Austria, Germany, Switzerland
Ages 18–80
A study can be open while its sites in Austria have not opened yet or have stopped. Only those recruiting at a site in Austria →
Of the 588 Coronary Artery Disease studies recruiting now, 403 (69%) set no upper age limit and 68 (12%) stop at 75 or younger; 38 take children under 18; 47 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
94 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 4 · Phase 3 15 · Phase 4 14
First in 1999; this study’s year is marked. 3 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 2,000 is above the median of 323 across 1,688 observational studies indexed under Coronary Artery Disease.
Median enrollment 1,191 across the 65 interventional studies, 1,000 across the 27 observational. Of the 56 that completed or were terminated, 21 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
50 of 94 have an industry lead sponsor. The 10 most frequent:
Vorarlberg Institute for Vascular Investigation and Treatment is the lead sponsor of 4 studies on the registry; 2 are open to participants now.
Vorarlberg Institute for Vascular Investigation and Treatment has 1 study filed under Coronary Artery Disease — fewer than ten, so there is no comparison to draw.
2 of the studies in Coronary Artery Disease with a site in Austria that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07588399Rayyan HemetsbergerSTRATegy SUccesS in High-Risk PCI With Impella CP: Evaluation of Hemodynamic Protection in Complex PCI | 2027-07-01 |
| NCT06779630TeleflexSafety and Effectiveness of the Orsiro Mission 48-mm Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions | 2027-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 94 studies in Coronary Artery Disease with a site in Austria, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This prospective observational cohort study investigates cardiovascular outcomes and associated risk factors in patients undergoing coronary angiography for suspected or established coronary artery disease at Feldkirch Regional Hospital in Vorarlberg, Austria.
The study aims to identify clinical, metabolic, laboratory, and lifestyle factors associated with coronary artery disease and subsequent cardiovascular events. Baseline assessments include clinical characteristics, cardiovascular risk factors, laboratory measurements, and lifestyle-related information.
The primary outcomes are all-cause mortality and cardiovascular events. Follow-up assessments are conducted approximately every two years through telephone interviews and review of available clinical records and databases. Mortality status and causes of death are assessed using data from Statistics Austria and available medical records. Long-term follow-up is planned to evaluate cardiovascular outcomes and changes in risk factors over time.
The study aims to enroll approximately 2,000 participants, with recruitment ongoing.
Coronary artery disease remains a major cause of morbidity and mortality despite advances in cardiovascular prevention, diagnosis, and treatment. Patients undergoing coronary angiography frequently present with cardiovascular risk factors and comorbidities, including diabetes mellitus, dyslipidemia, hypertension, and chronic kidney disease. Changes in therapeutic strategies highlight the need for contemporary prospective cohort data to improve cardiovascular risk assessment.
This study is designed to investigate the associations between clinical, metabolic, laboratory, and lifestyle-related characteristics and subsequent cardiovascular outcomes in patients undergoing clinically indicated coronary angiography for suspected or established stable coronary artery disease.
The study objectives include identifying risk factors associated with cardiovascular events and angiographically detectable coronary artery disease, evaluating longitudinal changes in anthropometric, lifestyle-related, and laboratory parameters, and investigating the relationships between cardiovascular and metabolic risk factors.
At baseline, participants undergo comprehensive clinical and laboratory assessments, including evaluation of cardiovascular risk factors, comorbidities, medication use, and lifestyle-related characteristics. Biological samples are collected for laboratory analyses and stored for further investigations.
Participants are followed approximately every two years through telephone interviews and review of available clinical records and databases to document nonfatal cardiovascular events and changes in relevant clinical characteristics. Mortality status and causes of death are assessed using data from Statistics Austria and available medical records.
The primary outcomes are all-cause mortality and cardiovascular events. Long-term follow-up is planned to investigate cardiovascular outcomes and their associations with baseline characteristics and risk factors over time.
The study population consists of consecutive adult patients (≥18 years) undergoing clinically indicated coronary angiography for the evaluation of suspected or established stable coronary artery disease at Feldkirch Regional Hospital, Austria. Eligible patients are prospectively enrolled after providing written informed consent. Patients presenting with acute coronary syndrome are excluded. The planned study population comprises approximately 2,000 participants.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adult patients undergoing clinically indicated coronary angiography for suspected or established stable coronary artery disease at Feldkirch Regional Hospital, Austria. Baseline clinical and laboratory assessments are performed at enrollment. Participants are prospectively followed to evaluate all-cause mortality, cardiovascular events, and associated risk factors. Follow-up data are collected through telephone interviews and queries of relevant clinical and administrative databases.
Procedure: Coronary Angiography
Coronary angiography performed as part of routine clinical care for the evaluation of suspected or established stable coronary artery disease. The procedure is clinically indicated and is not assigned by the study protocol.
Incidence of Cardiovascular Events
Occurrence of cardiovascular events within two years after baseline coronary angiography. Events are ascertained during follow-up and verified using available medical records.
Time frame: 2 years after baseline coronary angiography
All-Cause Mortality
All-cause mortality, defined as death from any cause within two years after baseline coronary angiography. Mortality status and causes of death are assessed using data from Statistics Austria and available medical records.
Time frame: 2 years after baseline coronary angiography
Plan to share: No — Individual participant data will not be made publicly available. Study data are pseudonymized and managed in accordance with applicable data protection regulations. No general sharing of individual participant data with external researchers is currently planned.
No publications or documents are linked to this record.
Started Mar 2022 (actual). Primary completion is estimated for Dec 2030, 105 months after the start.
Of 635 non-industry observational studies under Coronary Artery Disease, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 122. This study's planned 105 months is above that.
Counting every sponsor, half of 760 studies reached it within 41 months; a quarter within 21 and three quarters within 87.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Vorarlberg Institute for Vascular Investigation and Treatment